FY2026 EPS Estimates for Tourmaline Bio Decreased by Analyst

Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Analysts at Leerink Partnrs cut their FY2026 earnings per share (EPS) estimates for shares of Tourmaline Bio in a research note issued on Wednesday, May 21st. Leerink Partnrs analyst T. Smith now expects that the company will post earnings per share of ($4.45) for the year, down from their previous forecast of ($4.28). The consensus estimate for Tourmaline Bio's current full-year earnings is ($3.02) per share. Leerink Partnrs also issued estimates for Tourmaline Bio's FY2027 earnings at ($5.65) EPS, FY2028 earnings at ($7.45) EPS and FY2029 earnings at ($4.61) EPS.

A number of other research analysts have also recently commented on TRML. Chardan Capital reaffirmed a "buy" rating and set a $70.00 target price on shares of Tourmaline Bio in a research note on Monday, May 5th. Wedbush upped their price objective on Tourmaline Bio from $42.00 to $43.00 and gave the company an "outperform" rating in a research report on Friday, March 14th. HC Wainwright reiterated a "buy" rating and set a $50.00 target price on shares of Tourmaline Bio in a research report on Monday, May 5th. Finally, Lifesci Capital started coverage on shares of Tourmaline Bio in a report on Monday, February 24th. They issued an "outperform" rating and a $58.00 price target on the stock. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Tourmaline Bio currently has a consensus rating of "Buy" and a consensus price target of $49.33.

Tourmaline Bio Stock Down 0.9%

NASDAQ:TRML traded down $0.15 during mid-day trading on Monday, hitting $16.37. 13,718 shares of the stock traded hands, compared to its average volume of 322,525. Tourmaline Bio has a 52 week low of $11.56 and a 52 week high of $29.79. The stock has a market capitalization of $420.34 million, a price-to-earnings ratio of -5.79 and a beta of 2.11. The firm's 50 day moving average is $15.33 and its two-hundred day moving average is $17.67.

Tourmaline Bio (NASDAQ:TRML - Get Free Report) last posted its quarterly earnings data on Friday, May 2nd. The company reported ($0.89) EPS for the quarter, topping the consensus estimate of ($0.91) by $0.02.

Hedge Funds Weigh In On Tourmaline Bio

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Tower Research Capital LLC TRC lifted its stake in Tourmaline Bio by 297.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,646 shares of the company's stock worth $33,000 after acquiring an additional 1,232 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in shares of Tourmaline Bio in the 4th quarter worth approximately $47,000. Brooklyn Investment Group lifted its position in shares of Tourmaline Bio by 148.9% in the 1st quarter. Brooklyn Investment Group now owns 3,923 shares of the company's stock worth $60,000 after purchasing an additional 2,347 shares during the period. Virtus ETF Advisers LLC bought a new position in shares of Tourmaline Bio during the fourth quarter valued at approximately $64,000. Finally, GAMMA Investing LLC increased its holdings in Tourmaline Bio by 4,481.7% during the first quarter. GAMMA Investing LLC now owns 7,514 shares of the company's stock valued at $114,000 after buying an additional 7,350 shares during the period. Institutional investors own 91.89% of the company's stock.

Tourmaline Bio Company Profile

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.